Published: November 10, 2025
Key takeaways
- U.S. stock futures point higher as Washington inches toward ending the record government shutdown, with AI leaders rebounding ahead of the open.
- Pfizer wins the $10B bidding war for Metsera; Novo Nordisk bows out and shares climb in Copenhagen.
- Rumble jumps after striking an all‑stock deal to buy Germany’s Northern Data, adding tens of thousands of Nvidia GPUs and a Tether-backed leasing pact.
- Tyson Foods posts Q4 results and guides FY2026 revenue higher as chicken offsets beef headwinds.
Market snapshot: AI leads early rebound
U.S. index futures moved higher Monday as Senate action over the weekend boosted hopes for a stopgap funding bill to end the record federal shutdown. Nasdaq 100 futures led gains and AI bellwether Nvidia (NASDAQ: NVDA) traded about 3% higher premarket, pacing a broader chip bounce.
Adding to the tone, Nvidia CEO Jensen Huang said over the weekend that demand for the company’s next‑gen Blackwell platform remains “very strong,” underscoring continued wafer needs from TSMC. The remarks come as investors look to AI hardware leaders to reassert momentum after last week’s pullback. Reuters
What’s next: Nvidia’s Q3 FY26 results arrive Wednesday, November 19 after the bell—an event likely to set the near‑term tone for mega‑cap AI.
Deal watch: Pfizer takes Metsera in $10B obesity-drug play
Pfizer (NYSE: PFE) sealed a revised agreement to acquire Metsera (NASDAQ: MTSR) for $86.25 per share, including $65.60 in cash plus up to $20.65 via contingent value rights—capping a fast‑moving bidding war with Novo Nordisk (NYSE: NVO). Metsera’s board backed the sweetened deal Friday; closing is expected shortly after a Nov. 13 shareholder vote.
Investors repositioned Monday: Novo Nordisk shares rose roughly 3% in early Copenhagen trade after the company exited the contest, while Metsera traded lower in U.S. premarket action. Markets framed Novo’s retreat as disciplined capital allocation in a red‑hot obesity market that’s still crowded with pipeline risk.
Social & AI infrastructure: Rumble buys Northern Data
Video platform Rumble (NASDAQ: RUM) agreed to acquire German AI‑cloud operator Northern Data in an all‑stock deal valued around $767 million. Terms include 2.0281 new Rumble Class A shares per Northern Data share, a $150M GPU‑leasing agreement with Tether (an anchor customer), and access to ~22,400 Nvidia GPUs at close. Rumble shares surged more than 25% premarket on the announcement.
Why it matters: The move vaults Rumble deeper into AI infrastructure just as compute capacity becomes a competitive moat for model training and inference—potentially opening new revenue lines beyond video.
Consumer staples: Tyson leans on chicken, trims beef exposure pain
Tyson Foods (NYSE: TSN) guided FY2026 revenue up 2%–4%, topping the Street’s 2.3% view, as resilient demand for chicken and prepared foods helps blunt historically tight U.S. cattle supplies. Q4 net sales rose to $13.86B (slightly below consensus $13.97B), with chicken volumes +3.8% and beef volumes −8.4% amid record cattle costs.
The company said inflation‑weary consumers are cooking more at home, favoring lower‑priced proteins, and noted the long cattle‑cycle timeline before beef supply fully normalizes.
Stocks to watch the rest of the day
- Nvidia (NVDA): Pre‑earnings rebound with fresh CEO commentary on Blackwell demand and supply chain dynamics. Watch for any additional headlines on TSMC capacity.
- Metsera (MTSR), Pfizer (PFE), Novo Nordisk (NVO): Spread trading likely as arbitrageurs price Pfizer’s CVR structure and as Novo investors digest the decision to exit. Key date: Nov. 13 Metsera shareholder meeting.
- Rumble (RUM): Volatility risk remains as investors model GPU monetization, capex needs, and integration timing (deal expected to close Q2 2026).
- Tyson Foods (TSN): Guidance tone skews constructive; watch management color on commodity costs and pricing elasticity into the holiday period.
Editor’s note
This article focuses on the topics and tickers highlighted by Bloomberg/WSJ/Seeking Alpha roundups for November 10, 2025—namely Nvidia, Pfizer, Novo Nordisk, Rumble, Metsera, and Tyson Foods—and cross‑references primary reporting and company disclosures published today. Sources are linked inline.
Disclosure: This content is for information only and does not constitute investment advice.
